Clinical efficacy of erlotinib in patients previously treated for advanced non-small cell lung cancer

Respirology

Volumn 14, Issue 5, 2009, Pages 709-715

  Zhou, Songwen ^a   Ren, Shengxiang ^a   Yan, Lianghua ^a   Zhang, Ling ^a   Tang, Liang ^a   Zhang, Jie ^a   Zhou, Caicun ^a  

^a SHANGHAI PULMONARY HOSPITAL   (China)

Author keywords

Carcinoma; Epidermal growth factor receptor; Erlotinib; Non small cell lung; Tyrosine kinase inhibitor

Indexed keywords

ERLOTINIB; LOPERAMIDE; TRANSFORMING GROWTH FACTOR ALPHA; VASCULOTROPIN;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER GROWTH; CHINESE; CLINICAL TRIAL; DIARRHEA; DISEASE SEVERITY; DRUG EFFICACY; DRUG ERUPTION; DRUG FATALITY; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; DRY SKIN; DYSPNEA; ENZYME LINKED IMMUNOSORBENT ASSAY; FATIGUE; FEMALE; HUMAN; INTERSTITIAL LUNG DISEASE; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; NAUSEA; OVERALL SURVIVAL; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN BLOOD LEVEL; PRURITUS; SIDE EFFECT; STOMATITIS; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RETROSPECTIVE STUDIES; SURVIVAL RATE; TRANSFORMING GROWTH FACTOR ALPHA; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 68149105809     PISSN: 13237799     EISSN: 14401843     Source Type: Journal    
DOI: 10.1111/j.1440-1843.2009.01564.x     Document Type: Article

References (18)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J et al. Cancer statistics, 2007. CA Cancer J. Clin. 2007 57 : 43 66.
2. Weir HK, Thun MJ, Hankey BF, Ries LA, Howe HL et al. Annual report to the nation on the status of cancer, 1975-2000, featuring the uses of surveillance data for cancer prevention and control. J. Natl. Cancer Inst. 2003 95 : 1276 99.
3. Schiller JH, Harrington D, Belani CP, Langer C, Sandler A et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N. Engl. J. Med. 2002 346 : 92 8.
4. Onn A, Correa A, Gilcrease M, Isobe T, Massarelli E et al. Synchronous overexpression of epidermal growth factor receptor and HER@-neu protein is a predictor of poor outcome in patients with state I non-small cell lung cancer. Clin. Cancer Res. 2004 10 : 136 43.
5. Mendelsohn J, Baselga J. The EGF receptor family as targets for cancer therapy. Oncogene. 2000 19 : 6550 65.
6. Baselga J, Arteaga C. Critical update and emerging trends in epidermal growth factor receptor targeting in cancer. J. Clin. Oncol. 2005 23 : 2445 59.
7. Kris MG, Natale RB, Herbst RS, Lynch TJ Jr., Prager D et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 2003 290 : 2149 58.
8. Shepherd FA, Rodrigues Pereira JR, Ciuleanu T, Tan EH, Hirch V et al. Erlotinib in previously treated non-small-cell lung cancer. N. Engl. J. Med. 2005 353 : 123 32.
9. Tsao MS, Sakurada A, Cutz JC, Zhu CQ, Kamel-Reid S et al. Erlotinib in lung cancer-molecular and clinical predictors of outcome. N. Engl. J. Med. 2005 353 : 133 44.
10. Daniele L, Macrì L, Schena M, Dongiovanni D, Bonello L et al. Predicting gefitinib responsiveness in lung cancer by fluorescence in situ hybridization/chromogenic in situ hybridization analysis of EGFR and HER2 in biopsy and cytology specimens. Mol. Cancer Ther. 2007 6 : 1223 9.
11. Ushijima C, Tsukamoto S, Yamazaki K, Yoshino I, Sugio K et al. High vascularity in the peripheral region of non-small cell lung cancer tissue is associated with tumor progression. Lung Cancer. 2001 34 : 233 41.
12. Ravindranath N, Wion D, Brachet P, Djakiew D. Epidermal growth factor modulates the expression of vascular endothelial growth factor in the human prostate. J. Androl. 2001 22 : 432 43.
13. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS et al. New guidelines to evaluate the response to treatment in solid tumors. J. Natl. Cancer Inst. 2000 92 : 205 16.
14. Chen YM. Clinical application of epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKI) against non-small cell lung cancer (NSCLC). J. Cancer Mol. 2005 1 : 83 91.
15. Schneider C, Schott-vonRomer K, Gutz S, Raack B, Dierkesmann R et al. Biomarker analysis from TRUST, a trial of erlotinib in non-small cell lung cancer(NSCLC). Proc. Am. Soc. Clin. Oncol. 2007 25 : a76 74.
16. British Thoracic Society. Guidelines on diagnostic flexible bronchoscopy. Subcommittee on Standards of Care Committee, British Thoracic Society. Thorax. 2001 56 : 1 21.
17. Ishikawa N, DaigoY Yasui W, Inai K, Nishimura H et al. ADAM8 as a novel serological and histochemical marker for lung cancer. Clin. Cancer Res. 2004 10 : 8363 70.
18. Ishikawa N, Daigo Y, Takano A, Taniwaki M, Kato T et al. Increases of Amphiregulin and Transforming Growth Factor-α in Serum as Predictors of Poor Response to Gefitinib among Patients with Advanced Non-Small Cell Lung Cancers. Cancer Res. 2005 65 : 9176 84.